Windtree Therapeutics Engages New Growth Advisors for Potential Strategic Transaction

Dec 04, 2024•about 1 year ago

Contract Type

partnership

PennsylvaniaTherapeuticsPharmaceuticalBiotechnologyHealth Care

Description

Windtree Therapeutics has engaged New Growth Advisors as its strategic advisor to explore opportunities regarding its cardiovascular portfolio, including a potential out-licensing transaction or asset sale. The company seeks to leverage positive results for istaroxime in addressing diverse opportunities and securing potentially non-dilutive funding via a partnership.

Company Information

Company

Windtree Therapeutics

Location

Pennsylvania, United States

About

Windtree Therapeutics, Inc. is a pharmaceutical company focused on developing novel therapeutics for the treatment of a broad range of diseases. The company is publicly listed on NasdaqCM under the ticker symbol WINT and has a strong emphasis on advancing and commercializing innovative product candidates.

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months